Pipeline

 

 

Pipeline

Discovery
Lead Optimisation
Preclinical
Phase I
Phase II
Phase III

NAIAP-OL20-01

2020
2020
2021
2023

MIAMI-Ol20-11

2020
2022
2023
2025

Combo-Ol20-21

2021

Program

NAIAP Program

A collaboration with the university of Rennes in Pr. Felden’s Team (Bacterial Regulatory RNAs & Medicine), we developed news molecules that have the ability to kill pathogenic resistant bacteria. Moreover, these original molecules are able to eliminate the persisters that are responsible of infectious relapses. Based on these properties several molecules were designed and preclinical data leads us to select the lead candidate OL20-01. We are now performing the required experiments to start clinical studies.

MIAMI Program

After 20 years of research development and commercialization of products to fight against antibiotic resistance, the Olmix group has found and licensed a new molecule discovered in algae. This molecule has the property of boosting the immune system in immunodepressed preclinical models and thus could benefit to the patient to avoid nosocomial diseases. The molecule is being isolated, characterized and is now being processed toward preclinical development.

Combo Program

The synergies between Ol20-01 and Ol20-11 will also be tested as boosting the immune system and having a very potent anti-infective could be key to treat imminent life threatening conditions. Although combo experiments look promising, both molecules have yet to be further developed in collaboration with academic partners before considering preclinical studies.